1. Home
  2. WAFU vs BCDA Comparison

WAFU vs BCDA Comparison

Compare WAFU & BCDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Wah Fu Education Group Limited

WAFU

Wah Fu Education Group Limited

N/A

Current Price

$1.52

Market Cap

7.2M

Sector

Real Estate

ML Signal

N/A

BCDA

BioCardia Inc.

HOLD

Current Price

$1.27

Market Cap

14.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
WAFU
BCDA
Founded
1999
N/A
Country
China
United States
Employees
N/A
N/A
Industry
Other Consumer Services
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
7.2M
14.5M
IPO Year
2019
N/A

Fundamental Metrics

Financial Performance
Metric
WAFU
BCDA
Price
$1.52
$1.27
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$25.00
AVG Volume (30 Days)
12.5K
99.9K
Earning Date
01-01-0001
11-12-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$6,186,645.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.22
$1.00
52 Week High
$7.49
$3.20

Technical Indicators

Market Signals
Indicator
WAFU
BCDA
Relative Strength Index (RSI) 52.44 44.90
Support Level $1.51 $1.16
Resistance Level $1.65 $1.34
Average True Range (ATR) 0.08 0.09
MACD 0.01 -0.01
Stochastic Oscillator 51.86 32.79

Price Performance

Historical Comparison
WAFU
BCDA

About WAFU Wah Fu Education Group Limited

Wah Fu Education Group Ltd is involved in providing online exam preparation services and related technology solutions, and also produces online training course materials in China. It develops online educational materials that are offered through the cloud and that can be used for a wide range of purposes, such as standard examination preparation, professional training, and interactive programs for educational purposes other than exam preparation. Its segments are Online Education Services and Technological Development and Operation Service. The company generates maximum revenue from the Online Education Services segment.

About BCDA BioCardia Inc.

BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an off the shelf cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).

Share on Social Networks: